New Jersey-based Becton, Dickinson and Company’s India affiliate BD India has signed a deal with Israel’s Sight Diagnostics by which it will market SightDX’s Parasight Malaria Detection Platform in India, reports India Medical Times. Varun Khanna, managing director, BD India and South Asia, said, “Our collaboration with Sight Diagnostics is aligned with our purpose of advancing the world of health by bringing technology solutions for malaria diagnosis to India.”
According to Sight Diagnostics, the Parasight device is a platform for blood analysis. When used with the Malaria test kit, it combines computer-vision algorithms (image processing) to rapidly identify and quantify blood components (e.g. red blood cells) and blood anomalies (e.g. parasites) in an automated fashion, and in less than 4 minutes, a report is created with the diagnosis (Positive/Negative), parasitemia count (percentage of infected red blood cells), and speciation (determination of the specific species of malaria)
Yossi Pollak, CEO, SightDX, said, “Our collaboration with BD provides us with an established and experienced partner in the field of infectious disease, and together we can better serve the Indian healthcare market.”
